A Randomised, Double-blind, Double-dummy, Placebo-controlled, Multicentre, 6-way Crossover, Single-dose, Phase IIa Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 Administered Via Single Inhalation Device Compared to AZD3199 Administered Via Turbuhaler™ Inhaler in Patients With Asthma

Trial Profile

A Randomised, Double-blind, Double-dummy, Placebo-controlled, Multicentre, 6-way Crossover, Single-dose, Phase IIa Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 Administered Via Single Inhalation Device Compared to AZD3199 Administered Via Turbuhaler™ Inhaler in Patients With Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2013

At a glance

  • Drugs AZD 3199 (Primary)
  • Indications Asthma
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 15 Jun 2012 Actual patient number changed from 38 to 39 according to ClinicalTrials.gov.
    • 20 Mar 2012 Status changed from active, no longer recruiting to completed as reported by EudraCT.
    • 20 Mar 2012 Actual end date 27 Feb 2012 added as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top